| pubmed-article:9006785 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C0039771 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C0016976 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:9006785 | lifeskim:mentions | umls-concept:C1140999 | lld:lifeskim |
| pubmed-article:9006785 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:9006785 | pubmed:dateCreated | 1997-3-17 | lld:pubmed |
| pubmed-article:9006785 | pubmed:abstractText | Bile excretion might change the physiological milieu of the duodenum resulting in enhanced absorption of a drug due to increased solubilisation. This possible influence of bile salts following stimulation of gallbladder emptying via the release of cholecystokinin on the pharmacokinetics of a sustained-release theophylline (CAS 58-55-9) preparation (Bronchoretard) was evaluated in this study. An open, randomised 3-way cross-over study in 12 healthy, non-smoking volunteers was selected to prove or reject this hypothesis. All subjects received 500 mg of the sustained-release theophylline formulation under two different cholagogia stimulating test conditions and under a fasting reference condition. A standard breakfast and i.m. application of cholecystokinin enabled modulation of bile flow; a moderate and extreme contraction of the gallbladder could be induced after a standard breakfast and after i.m. application of cholecystokinin, respectively. Following a standard breakfast, gallbladder volumes were approximately halved (50.6%) compared to the baseline volume after 79 min. Injection of 0.3 micrograms/kg body weight cholecystokinin resulted in quick and complete gallbladder evacuation (94.6%) 36 min after the application of this cholagogue stimulus. Gallbladder volumes remained approximately constant under fasting conditions. This manipulation of bile flow did not influence concentration/time profiles of the sustained-release theophylline preparation compared to the fasting condition. Even almost complete evacuation of the gallbladder after application of cholecystokinin did not modify concentration/time profiles of theophylline in a relevant way. An unintentional rapid release of theophylline could be excluded for this sustained-release formulation for all three treatments, as not a single case of dose-dumping was observed. Furthermore, in vitro dissolution investigations using surfactants are neither predictive of food effects nor bile influence on in vivo absorption at least for the sustained-release formulation tested. | lld:pubmed |
| pubmed-article:9006785 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9006785 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9006785 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9006785 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9006785 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9006785 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9006785 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9006785 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9006785 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:9006785 | pubmed:issn | 0004-4172 | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:WeilAA | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:PopescuGG | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:GaySS | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:StanislausFF | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:von... | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:BarkworthM... | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:MolzK HKH | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:LaicherAA | lld:pubmed |
| pubmed-article:9006785 | pubmed:author | pubmed-author:FuchsW SWS | lld:pubmed |
| pubmed-article:9006785 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9006785 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:9006785 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9006785 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9006785 | pubmed:pagination | 1120-6 | lld:pubmed |
| pubmed-article:9006785 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:meshHeading | pubmed-meshheading:9006785-... | lld:pubmed |
| pubmed-article:9006785 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:9006785 | pubmed:articleTitle | Effect of gallbladder contraction induced cholagogia on the pharmacokinetic profile of a sustained-release theophylline formulation. | lld:pubmed |
| pubmed-article:9006785 | pubmed:affiliation | Klinge Pharma GmbH, Munich, Germany. | lld:pubmed |
| pubmed-article:9006785 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9006785 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9006785 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
